Nevro (NVRO) Stock Forecast & Price Target

$9.74

-0.14 (-1.42%)

(As of 07/26/2024 ET)

Nevro - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Reduce
Based on 13 Analyst Ratings

Based on 13 Wall Street analysts who have issued ratings for Nevro in the last 12 months, the stock has a consensus rating of "Reduce." Out of the 13 analysts, 2 have given a sell rating, 10 have given a hold rating, and 1 has given a buy rating for NVRO.

Consensus Price Target

$17.71
81.80% Upside

High Forecast	$40.00
Average Forecast	$17.71
Low Forecast	$8.20

According to the 13 analysts' twelve-month price targets for Nevro, the average price target is $17.71. The highest price target for NVRO is $40.00, while the lowest price target for NVRO is $8.20. The average price target represents a forecasted upside of 81.80% from the current price of $9.74.

Type	Current Forecast 7/28/23 to 7/27/24	1 Month Ago 6/28/23 to 6/27/24	3 Months Ago 4/29/23 to 4/28/24	1 Year Ago 7/28/22 to 7/28/23
Consensus Rating	Reduce	Reduce	Hold	Hold
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	1 Buy rating(s)	1 Buy rating(s)	1 Buy rating(s)	3 Buy rating(s)
Hold	10 Hold rating(s)	10 Hold rating(s)	11 Hold rating(s)	8 Hold rating(s)
Sell	2 Sell rating(s)	2 Sell rating(s)	1 Sell rating(s)	2 Sell rating(s)
Consensus Price Target	$17.71	$19.46	$21.23	$36.50
Forecasted Upside	81.80% Upside	26.91% Upside	25.15% Upside	13.92% Upside

Get Nevro Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for NVRO and its competitors with MarketBeat's FREE daily newsletter.

Ad Stansberry Research

Get out of cash before the Fed's next meeting

"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all $20,000 of his wife's 401k into shares of just ONE stock. Everyone on Wall Street said he was crazy. But a year later, that $20,000 in his wife's account was worth $120,000. Today, he says: "If you thought the dot-com mania was intense, what's about to happen in the coming weeks could be even crazier and could open up a new window of opportunity for 500%-plus gains."

Click here now to watch this exclusive interview

NVRO Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

NVRO Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Nevro Stock vs. The Competition

Type	Nevro	Medical Companies	S&P 500
Consensus Rating Score	1.92	2.72	2.50
Consensus Rating	Reduce	Moderate Buy	Moderate Buy
Predicted Upside	81.80% Upside	3,123.51% Upside	9.18% Upside
News Sentiment Rating	Neutral News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
7/16/2024	Truist Financial 1 of 5 stars		Lower Target	Hold ➝ Hold	$11.00 ➝ $10.00	+1.94%
7/15/2024	Morgan Stanley 3 of 5 stars		Lower Target	Equal Weight ➝ Equal Weight	$14.00 ➝ $9.00	-4.26%
7/10/2024	Citigroup 3 of 5 stars		Lower Target	Sell ➝ Sell	$9.00 ➝ $8.20	+2.37%
5/8/2024	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Hold ➝ Hold	$17.00 ➝ $11.00	+5.97%
5/8/2024	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Equal Weight ➝ Equal Weight	$14.00 ➝ $13.00	+23.46%
5/8/2024	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Underweight ➝ Underweight	$15.00 ➝ $12.00	+4.08%
Get the Latest News and Ratings for NVRO and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Nevro and its competitors with MarketBeat's FREE daily newsletter.
4/15/2024	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Sector Perform ➝ Sector Perform	$18.00 ➝ $16.00	+28.62%
4/11/2024	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Neutral ➝ Neutral	$20.00 ➝ $16.00	+20.30%
2/22/2024	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Neutral ➝ Neutral	$23.00 ➝ $19.00	+15.15%
2/22/2024	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Outperform ➝ Market Perform
11/2/2023	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Neutral ➝ Neutral	$23.00 ➝ $18.00	+20.00%
8/2/2023	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$75.00 ➝ $40.00	+62.14%
11/2/2022	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	B. Vazquez Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform
10/12/2022	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Underperform	$31.00	-16.98%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 05:37 AM ET.

NVRO Forecast - Frequently Asked Questions

What is Nevro's forecast for 2024?: According to the research reports of 13 Wall Street equities research analysts, the average twelve-month stock price forecast for Nevro is $17.71, with a high forecast of $40.00 and a low forecast of $8.20.
Should I buy or sell Nevro stock right now?: 13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nevro in the last twelve months. There are currently 2 sell ratings, 10 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "reduce" NVRO shares.
Does Nevro's stock price have much upside?: According to analysts, Nevro's stock has a predicted upside of 28.20% based on their 12-month stock forecasts.
Has Nevro been downgraded by Wall Street analysts recently?: Over the previous 90 days, Nevro's stock had 1 downgrade by analysts.
What analysts cover Nevro?: Nevro has been rated by research analysts at Canaccord Genuity Group, Citigroup, Morgan Stanley, Piper Sandler, Truist Financial, and Wells Fargo & Company in the past 90 days.
Do Wall Street analysts like Nevro more than its competitors?: Analysts like Nevro less than other "medical" companies. The consensus rating for Nevro is Reduce while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how NVRO compares to other companies.